Clinical Significance of Computer Aided Image Analysis in Treatment Response Evaluation of Lung Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03954847

Enrollment

1000

Registered

2019-05-17

Start date

2012-01-01

Completion date

2020-12-31

Last updated

2019-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Lung cancer, Image, Treatment response, Prognosis, Radiomic, Deep learning

Brief summary

The investigators will evaluate the utility of computer aided image analysis in lung cancer with the aim of predicting treatment response and prognosis.

Detailed description

Tumor biological behavior is the fundamental cause of heterogeneous prognosis. The features found on medical images are also reflections of the tumor biological behavior. However, the limitations in spatial and intensity resolution of the naked eye are two inevitable shortcomings of image interpretation by naked eyes, resulting in subjective and limited analyses of images. Computer aided image analyses such as radiomic analysis and machine learning methods are emerging as promising image interpretation methods. The natural advantage of the unlimited spatial and intensity resolution of computers can overcome the shortcomings of visual inspection with the naked eye. Moreover, the massive computing power of computer is also far greater than that of humans. This study will focus on the application of computer aided analysis in predicting treatment response and prognosis in lung cancer.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients \>= 18 years old 2. Pathological diagnosis of NSCLC between 2012 and 2019; 3. PET/CT or CT examination before any cancer-specific treatment;

Exclusion criteria

1. A time interval between treatment and image examination greater than 1 month; 2. A history of other malignancies

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	2012-2021	The interval between the date of diagnosis and death

Secondary

Measure	Time frame	Description
Progression free survival	2012-2021	The interval between the date of treatment initiation and disease progression

Countries

China

Contacts

Primary ContactYang Jin, MD

whuhjy@126.com027-85755457

Outcome results